Clinical Biomarkers for Pediatric Infectious Mononucleosis Treatment Response

171 pediatric patient records track D-dimer and CRP/albumin ratio changes to predict complication risk in infectious mononucleosis. The composite biomarker model achieved an area under the curve of 0.91 in the training cohort and 0.93 in validation. Authored by Long Ying Zhu and shared under a CC-BY-4.0 license, this dataset was last updated in May 2026.

Use Cases

• Predicting complication risk in pediatric infectious mononucleosis based on fever duration and biomarker changes.
• Evaluating therapeutic efficacy using short-term changes in D-dimer and CRP/albumin ratio.
• Validating a composite biomarker model for risk stratification in a clinical validation cohort.
• Analyzing the relationship between persistent hypercoagulability, inflammation, and clinical outcomes.

Strengths

• Dataset includes 171 patient records with a clear split between complication (n=55) and no-complication (n=116) groups.
• Model performance is validated with specific metrics: AUC of 0.91 (95% CI 0.86–0.96), sensitivity of 0.85, and specificity of 0.86.
• Analysis includes measurements at two time points (admission and day five) to calculate rates of change for key biomarkers.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic or institutional bias inherent to the single-hospital study design.

Provenance

Source

figshare

Collection Method

Clinical study involving 171 hospitalized children diagnosed with infectious mononucleosis.

Freshness

Last updated 2026-05-15 05:50:52; freshness should be verified.